ITGB1 and cancer: CD29‐high Tregs also promote cancer progression through EMT: CD29+ Tregs, characterised by high CD29 expression, proliferate robustly in the liver, fill Treg niches and exhibit strong immunosuppressive functions, impairing ICI (immune checkpoint inhibitor) therapy efficacy against liver tumours [61].